Literature DB >> 18514376

Modulation of high-frequency oscillations associated with NMDA receptor hypofunction in the rodent nucleus accumbens by lamotrigine.

Mark J Hunt1, Rene Garcia, Charles H Large, Stefan Kasicki.   

Abstract

We reported recently that ketamine can increase the power of high-frequency oscillations (HFO) in the rodent nucleus accumbens (NAc), a region implicated in the pathophysiology of schizophrenia. Lamotrigine is known to reduce several of the abnormal behaviors induced by NMDA receptor antagonists in humans and rodents. This prompted us to examine whether lamotrigine would disrupt ketamine-enhanced HFO. Local field potentials (LFPs) and locomotor activity were recorded from male Wistar rats chronically implanted with electrodes in the NAc. Rats were pretreated with either saline or lamotrigine for 60min followed by injection of ketamine (25mg/kg). A separate group received a unilateral intra-NAc infusion of lamotrigine immediately followed by systemic injection of ketamine. We found systemic injection of a high dose of lamotrigine (20.1mg/kg) reduced the power and frequency of ketamine-enhanced HFO. This dose of lamotrigine was also associated with a decrease in both spontaneous HFO and locomotor activity, but did not significantly reduce locomotor activity induced by ketamine. In contrast, a low dose of lamotrigine (2.0mg/kg) produced a small, but significant increase of both ketamine-enhanced HFO and locomotor activity. Local infusion of lamotrigine into the NAc did not significantly affect ketamine-induced HFO, suggesting lamotrigine produces its effect on structures afferent to the NAc, and effects on HFO most likely result from modulating excitatory transmission to the NAc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514376     DOI: 10.1016/j.pnpbp.2008.04.009

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

Review 1.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

2.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

3.  Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.

Authors:  L Elliot Hong; Ann Summerfelt; Robert W Buchanan; Patricio O'Donnell; Gunvant K Thaker; Martin A Weiler; Adrienne C Lahti
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

4.  A PK-PD model of ketamine-induced high-frequency oscillations.

Authors:  Francisco J Flores; ShiNung Ching; Katharine Hartnack; Amanda B Fath; Patrick L Purdon; Matthew A Wilson; Emery N Brown
Journal:  J Neural Eng       Date:  2015-08-13       Impact factor: 5.379

Review 5.  In vivo electrophysiological recordings of the effects of antidepressant drugs.

Authors:  Paul J Fitzgerald; Brendon O Watson
Journal:  Exp Brain Res       Date:  2019-05-11       Impact factor: 1.972

Review 6.  Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review.

Authors:  Alina Wilkowska; Mariusz S Wiglusz; Katarzyna Jakuszkowiak-Wojten; Wiesław J Cubała
Journal:  Cells       Date:  2022-02-12       Impact factor: 6.600

7.  Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens.

Authors:  Sailaja A Goda; Joanna Piasecka; Maciej Olszewski; Stefan Kasicki; Mark J Hunt
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.